Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 3, May-June, p. 549–553

doi: 10.17219/acem/61855

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Prognostic factors in pulmonary arterial hypertension: Literature review

Emilia Stępnowska1,A,D, Ewa Lewicka2,D,E, Alicja Dąbrowska-Kugacka2,E, Paweł Miękus1,F, Grzegorz Raczak2,F

1 Department of Cardiology, Saint Vincent de Paul Hospital, Gdynia, Poland

2 Department of Cardiology and Cardiac Electrotherapy, Medical University of Gdańsk, Poland

Abstract

Pulmonary arterial hypertension is a disease that has a bad influence on the patient’s prognosis. Recently, the possibility of therapy has dramatically changed. Nowadays, the treatment of this disease is concerned mainly with the pathophysiological target. In clinical practice, it is important to start therapy at the appropriate time, when the patient is qualified because of an unsatisfactory examination result or improve therapy when the patient is getting worse. The understanding of prognosis factors in pulmonary arterial hypertension is necessary, because it is used to determine the length of patients’ life expectancy. In September of 2015, new guidelines of ESC concerning the diagnosis and treatment of pulmonary hypertension have been presented. In our article we centered on the prognosis factor in pulmonary arterial hypertension. This document is a continuation of ESC guidelines. Many of the most contemporary articles are here summarized.

Key words

pulmonary arterial hypertension, prognosis, risk factor, mortality

References (29)

  1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2015. pii: ehv317.
  2. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. Turk Kardiyol Dern Ars. 2014;42(Suppl 1):55–66.
  3. Corciova FC, Arsenescu-Georgescu C. Prognostic factors in pulmonary hypertension. Maedica (Buchar). 2012;7(1):30–37.
  4. Manes A, Palazzini M, Leci E, et al. Current era survival of patient with pulmonary arterial hypertension associated with congenital heart disease: A comparison between clinical subgroups. Eur Heart J. 2014;35(11):716–724.
  5. York M, Faber HW. Pulmonary hypertension: Screening and evaluation in scleroderma. Curr Opin Rheumatol. 2011;23(6):536–544.
  6. Math SC, Hummers LK, Champion HC, Wigley FM, Zaiman A. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. Arthritis Rheum. 2009;60(2):569–577.
  7. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: Insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122(2):164–172.
  8. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: The UK Pulmonary Hypertension Service for Children 2001-2006. Heart. 2009;95(4):312–317.
  9. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patient with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–349.
  10. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):589–596.
  11. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of randomized trials. J Am Coll Cardiol. 2012;60(13):1192–1201.
  12. Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015;34(3):362–368.
  13. Bendayan D, Shitrit D, Ygla M, et al. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. Respir Med. 2003;97(2):130–133.
  14. Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med. 1999;160(2):487–492.
  15. Hasday JD, Grum CM. Nocturnal increase of urinary uric acid:creatinine ratio: A biochemical correlate of sleep-associated hypoxemia. Am Rev Respir Dis. 1987;135(3):534–538.
  16. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102(8):865–870.
  17. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129(5):1313–1321.
  18. Blyth KG, Groenning BA, Mark PB, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J. 2007;29(4):737–744.
  19. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic pre capillary pulmonary hypertension. Circulation. 2003;108(7):844–848.
  20. Takeda Y, Takeda Y, Tomimoto S, et al. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. BMC Pulm Med. 2010;10:22.
  21. Eysmann SB, Palevsky HI, Reichek N, Hackney K, Douglas PS. Two-dimensional and doppler echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation. 1989;80(2):353–360.
  22. Howard LS. Prognostic Factors in pulmonary arterial hypertension: Assessing the course of the disease. Eur Respir Rev. 2011;20(122):236–242.
  23. Ghio S, Klersy C, Margin G, et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. Int J Cardiol. 2010;140(3):272–278.
  24. Stone AC, Klinger JR. The right ventricle in pulmonary hypertension. In: Contemporary cardiology: Pulmonary hypertension. Red.: NS Hill I HW Farber. Totowa, NJ: Humana Press. 2008:93–125.
  25. Ghio S, Pazzano AS, Klersy C, et al. Clinical and prognostic relevance of echocardiographic evaluation of right ventricular geometry in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol. 2011;107(4):628–632.
  26. Grunig E, Tiede H, Enyimayew EO, et al. Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. Circulation. 2013;128(18):2005–2015.
  27. Bustamante-Labarta M, Perrone S, de la Fuente RL, et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocardiogr. 2002;15(10 Pt 2):1160–1164.
  28. Bradlow WM, Assomull RG, Williams F, et al. Cardiovascular magnetic resonance measured right ventricular mass influences prognosis in pulmonary arterial hypertension. Eur Heart J. 2010;31:8.
  29. Van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28(10):1250–1257.
© Wroclaw Medical University